Assessment of insulin action in man: role of hyperglycemia

1988 ◽  
Vol 119 (2) ◽  
pp. 213-222 ◽  
Author(s):  
E. Martens ◽  
R. Zick ◽  
H. J. Mitzkat ◽  
A. von zur Mühlen ◽  
M. J. Müller

Abstract. The effect of hyperglycemia on insulin-induced glucose metabolism (M) was investigated in healthy subjects using sequential clamp protocols at constant insulin + somatostatin infusions and varying plasma glucose. During euglycemia (4.8 mmol/l) M increased from 5.6 to 12.5 mg·kg−1·min−1 with increasing plasma insulin (0.34-3.00 nmol/l). At increasing glucose (6.7 mmol/l), M further increased (9.7 to 19.2 mg·kg−1·min−1) with the plasma insulin level (0.41 to 2.99 nmol/l). At a plasma glucose level of 9.8 mmol/l insulin (0.42 to 3.17 nmol/l) was still effective to increase M (13.7 to 25.2 mg·kg−1·min−1). Regression analysis showed that hyperglycemia does not only increase the maximal insulin-stimulated M, but also decreases the insulin concentration causing a half maximum effect. During prolonged clamp studies M increased by about 10% per h, independent by the plasma glucose level. We conclude that hyperglycemia increases M by increasing insulin responsiveness as well as insulin sensitivity. Data derived from euglycemic clamp studies alone are of limited value with respect to the assessment of insulin action.

1987 ◽  
Vol 116 (3_Suppl) ◽  
pp. S182
Author(s):  
E. MARTENS ◽  
R. ZICK ◽  
H. J. MITZKAT ◽  
A. VON ZUR MÜHLEN ◽  
M. J. MÜLLER

1990 ◽  
Vol 123 (6) ◽  
pp. 661-667 ◽  
Author(s):  
Koichi Kawai ◽  
Seiji Suzuki ◽  
Shinichi Ohashi ◽  
Hidehito Mukai ◽  
Yasuko Murayma ◽  
...  

Abstract. The effects of truncated glucagon-like peptide-1 (GLP-1) on insulin and glucagon release were examined in unanesthetized normal dogs. A bolus injection of GLP-1 (7-36)amide elicited a transient increase in the plasma insulin level, which brought about a decrease in the plasma glucose level. The degree of increase in plasma insulin levels with GLP-1 (7-35)OH or GLP-1 (7-37)OH was less than that induced by GLP-1 (7-36)amide. The plasma glucagon level did not increase in spite of mild hypoglycemia. The infusion of graded doses of GLP-1 (7-36)amide (6, 36, 120 ng · kg−1 · min−1 every 30 min) did not change the plasma glucose, insulin or glucagon levels significantly. The degree of increase in the plasma glucose level induced by iv glucose infusion (12 mg · kg−1 · min−1) was reduced by coinfusion of GLP-1(7-36)amide (6 ng · kg−1 · min−1), although the degree of increase in the plasma insulin level was the same as that in a control experiment (coinfusion of the vehicle). Coinfusion of GLP-1 (7-36)amide (60 ng · kg−1 · min−1) caused an augmented increase in the plasma insulin level and a reduced increase in the plasma glucose level during iv glucose infusion (17 mg · kg−1 · min−1) compared with the control experiment. The degree of decrease in the plasma glucagon level during iv glucose infusion was not affected by the coinfusion. The degree of increase in the plasma glucagon level induced by insulin hypoglycemia and the profile of the plasma glucose level at that time were not affected by the infusion of GLP-1 (7-36)amide. These results demonstrate that 1. the insulinotropic activity of GLP-1 (7-36)amide is higher than that of GLP-1(7-37)OH or GLP-1(7-35)OH; 2. GLP-1 (7-36)amide suppresses the degree of increase in plasma glucose level during iv glucose infusion by augmented insulin release, and 3. the glucagonostatic activity of truncated GLP-1 is negligible under physiological conditions.


Sign in / Sign up

Export Citation Format

Share Document